Wedbush is not changing the firm’s positive bias on Viridian Therapeutics (VRDN) after its competitor Acelyrin (SLRN) hosted an investor event ...
In a report released today, Jay McCanless from Wedbush reiterated a Hold rating on Meritage (MTH – Research Report), with a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback